NAD+ Delivery Methods: IV, Nasal Spray & NMN Compared

For laboratory and research use only. This article summarises published scientific research on NAD+ delivery formats. Neurovia products are not intended for human consumption. See our disclaimer.

NAD+ Delivery Methods: IV, Nasal Spray & NMN Compared

As research interest in NAD+ biology has grown, so has the investigation into how NAD+ and its precursors can best be delivered in research and clinical contexts. The fundamental challenge — that NAD+ does not easily cross cell membranes directly, and is rapidly metabolised — has driven research into multiple delivery formats, each with distinct bioavailability profiles and research applications.

This article provides an evidence-based overview of the three primary NAD+ delivery formats studied in published research: intravenous NAD+, nasal spray delivery, and NMN as an oral precursor.

The Core Bioavailability Challenge

Understanding why delivery format matters requires understanding what happens to NAD+ in biological systems.

NAD+ is a relatively large, polar molecule (MW ~663 Da) with two phosphate groups that give it a significant negative charge at physiological pH. These properties mean:

  • Poor passive membrane permeability — charged polar molecules do not diffuse freely across lipid bilayers
  • Rapid extracellular degradation — extracellular NAD+ is rapidly broken down by CD38 and other ectoenzymes into NMR (nicotinamide riboside) and AMP
  • Active transport required — cellular NAD+ uptake relies on specific transport mechanisms that vary by tissue

The consequence is that simply raising plasma NAD+ levels does not guarantee equivalent increases in intracellular NAD+ across all tissues. This is why different delivery formats — and precursor approaches — have been studied as potential strategies for raising tissue-specific NAD+ levels in research.

Intravenous (IV) NAD+ Research

Intravenous administration delivers NAD+ directly into the bloodstream, bypassing gastrointestinal absorption and first-pass metabolism. This makes it the most studied format for achieving rapid, high plasma NAD+ concentrations in both preclinical and clinical research contexts.

Published IV NAD+ Research

Pharmacokinetic studies — Published human pharmacokinetic studies have examined the plasma NAD+ profile following IV infusion. Research published in Nature Communications and other journals has characterised how rapidly plasma NAD+ rises and falls following IV administration, and how this translates to tissue NAD+ levels in animal models.

Clinical research — IV NAD+ has been studied in clinical contexts including addiction research, neurodegenerative disease contexts, and ageing biology studies. Some of this research has been published in peer-reviewed journals; much remains in preprint or clinical trial stages.

NAD+ and the blood-brain barrier — One area of specific research interest with IV delivery is CNS penetration. Published preclinical research has examined whether IV-administered NAD+ or its metabolites can cross the blood-brain barrier, with implications for neurological research applications.

Limitations of IV Research

IV delivery requires clinical infrastructure, involves administration-associated factors that complicate research design, and is not practically scalable for many research contexts. These limitations have driven interest in alternative delivery formats.

Nasal Spray NAD+ Research

Intranasal delivery of NAD+ has attracted research interest based on two potential advantages:

  1. Olfactory route CNS access — the olfactory epithelium provides a pathway that bypasses the blood-brain barrier, allowing direct access to the CNS. This route has been studied for multiple neurologically active compounds including peptides and small molecules.
  1. Avoidance of first-pass metabolism — intranasal delivery, like IV, bypasses hepatic first-pass metabolism, potentially allowing more of the administered compound to reach systemic circulation.

Published Nasal NAD+ Research

Published research specifically on nasal NAD+ delivery is more limited than IV research. The broader literature on intranasal delivery of NAD+ precursors and neurologically active compounds informs the research rationale.

Preclinical research on intranasal delivery of small molecules and peptides — including published studies on intranasal insulin and intranasal glutathione — provides the mechanistic framework for nasal NAD+ research. Specific published data on nasal NAD+ bioavailability and tissue distribution in animal models is an emerging area rather than an established research field.

The research interest in nasal NAD+ delivery centres particularly on potential CNS applications — relevant to published NAD+ research in neurological and neurodegenerative contexts.

NMN (Nicotinamide Mononucleotide) Research

NMN is a direct precursor to NAD+ in the salvage biosynthesis pathway. The rationale for studying NMN as an NAD+ delivery strategy is that NMN may be more readily absorbed and converted to NAD+ intracellularly than direct NAD+ administration.

How NMN Becomes NAD+

NMN → NAD+ conversion is catalysed by NMNAT (NMN adenylyltransferase) enzymes. Published research has characterised three NMNAT isoforms (NMNAT1, 2, 3) with different subcellular and tissue distributions — relevant to understanding tissue-specific NAD+ biosynthesis from NMN.

Published NMN Research

Imai et al. studies — Shin-ichiro Imai’s group at Washington University published foundational NMN research in Cell Metabolism (2013, 2016), demonstrating that NMN administration restored NAD+ levels in aged mouse tissues and improved markers of metabolic function. These studies drove widespread research interest in NMN.

Clinical research — Multiple human clinical trials have now examined oral NMN and its effects on blood NAD+ levels and metabolic markers. Published trials include those examining NMN safety and pharmacokinetics in healthy adults, with data confirming that oral NMN raises blood NAD+ concentrations in human subjects.

Tissue distribution — Published research has examined which tissues preferentially take up NMN and convert it to NAD+, with different tissues showing different NAD+ biosynthetic capacity and NMN uptake rates.

What Is the Difference Between NAD+ and NMN?

NAD+ and NMN represent different points in the NAD+ biosynthesis pathway:

  NAD+ NMN
Form Active coenzyme NAD+ precursor
Molecular weight ~663 Da ~334 Da
Cell membrane permeability Limited — requires transporters Better — studied transporter Slc12a8
Route of administration studied IV, nasal Primarily oral
Published human trials Limited Multiple published trials
Conversion step None — active form Requires NMNAT conversion

A dedicated NMN transporter (Slc12a8) identified by Imai’s group in Nature Metabolism (2019) provided mechanistic support for direct NMN cellular uptake, independent of conversion to NMR, resolving an earlier debate in the published literature about NMN’s mechanism of cellular entry.

Supply Format for Research

Neurovia supplies the following NAD+-related research formats:

  • NAD+ 1000mg — lyophilised vial for IV and research use
  • NAD+ Nasal Spray — intranasal research delivery format
  • NMN Capsules 500mg — oral precursor research format

All supplied at 99% purity, third-party tested, with Certificate of Analysis available.

Further reading: peer-reviewed research on NAD+ delivery methods (PubMed).

Frequently Asked Questions

What is NAD IV research?

NAD+ intravenous research examines the pharmacokinetics, tissue distribution, and biological effects of IV-administered NAD+ in preclinical and clinical settings. It is studied as a method for achieving rapid, high plasma NAD+ concentrations, with applications in neurological, metabolic, and ageing research contexts.

What is NAD nasal spray research?

Nasal spray NAD+ research investigates intranasal delivery as a potential route for CNS-targeted NAD+ administration via the olfactory pathway. It represents an emerging research area informed by the broader literature on intranasal delivery of neurologically active compounds.

What is the difference between NAD+ and NMN?

NAD+ is the active coenzyme; NMN is a direct biosynthetic precursor. NMN is converted to NAD+ intracellularly by NMNAT enzymes. Published research suggests NMN may have better cellular uptake than direct NAD+ administration, particularly via a dedicated NMN transporter (Slc12a8) identified in animal studies.

Which is better for research — NAD+ IV or NMN oral?

This depends entirely on the research question. IV NAD+ is studied for rapid systemic NAD+ elevation and potential CNS applications. Oral NMN is more practical and has published human bioavailability data. For specific tissue-targeted or CNS-focused research, the delivery route is a key experimental variable.

Does NAD+ cross the blood-brain barrier?

Published preclinical research has examined this question with mixed findings. Some studies suggest that NAD+ metabolites (including NMR) may cross the BBB more readily than NAD+ itself. Intranasal delivery is being studied as a potential route for direct CNS access. This remains an active area of research.

What are NAD+ precursors?

NMN and NR (Nicotinamide Riboside) are the primary direct NAD+ precursors studied in research. Both are converted to NAD+ via different steps in the salvage pathway. Nicotinamide (NAM) and nicotinic acid (NA) are also NAD+ precursors via different biosynthetic routes.

This article summarises published peer-reviewed research on NAD+ delivery formats and is provided for informational purposes only. Neurovia’s NAD+ products are supplied for laboratory research use only and are not intended for human consumption. Full disclaimer →

Related Products & Research